Telomir Pharmaceuticals, Inc.

TELO

US87975F1049

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-09 pm EDT			5-day change	1st Jan Change
6.54 ^USD	+10.29%		-4.39%	0.00%

Apr. 16	Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C	CI
Apr. 12	Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors	CI

Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors

April 12, 2024 at 04:06 pm EDT

On April 10, 2024, Telomir Pharmaceuticals, Inc. (the ?Company?) received written notice of resignation from Christos Nicholoudis, Esq. resigning, with immediate effect, from his positions as the General Counsel and a member of the Board of Directors of the Company. Mr. Nicholoudis?

resignation was due to his desire to pursue other activities, and not as a result of a disagreement with the Company.

Latest news about Telomir Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C	Apr. 16	CI
Telomir Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis, Esq. as the General Counsel and A Member of the Board of Directors	Apr. 12	CI
Telomir Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines	Mar. 26	CI
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data for Its Lead Development Product At Singapore Conference	Mar. 07	CI
Telomir Pharmaceuticals, Inc.(NasdaqCM:TELO) added to NASDAQ Composite Index	Feb. 11	CI
Telomir Pharmaceuticals, Inc. has completed an IPO in the amount of $7 million.	Feb. 08	CI

Chart Telomir Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Companyâs BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TELOMIR PHARMACEUTICALS, INC.	0.00%	176M
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals